BRISTOL MYERS SQUIBB

🇫🇷France
Ownership
-
Established
1989-01-01
Employees
30K
Market Cap
$97.5B
Website
https://www.bms.com/

Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome

First Posted Date
2005-05-10
Last Posted Date
2011-04-15
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
400
Registration Number
NCT00110422
Locations
🇪🇸

Local Institution, Zaragoza, Spain

Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes

Phase 3
Completed
Conditions
First Posted Date
2005-04-01
Last Posted Date
2010-09-14
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
1440
Registration Number
NCT00106808
Locations
🇺🇦

Local Institution, Simferopol, Ukraine

Study of KOS-862 (Epothilone D) in Metastatic Prostate Cancer

Phase 2
Terminated
Conditions
First Posted Date
2005-02-24
Last Posted Date
2008-09-17
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
53
Registration Number
NCT00104130
Locations
🇺🇸

Georgia Cancer Specialists, Tucker, Georgia, United States

🇺🇸

Kaiser Permanente NW Oncology Clinic, Portland, Oregon, United States

🇺🇸

Kaiser Permanente Medical Center, Vallejo, California, United States

and more 6 locations

Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia

First Posted Date
2005-02-16
Last Posted Date
2010-08-10
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
150
Registration Number
NCT00103844
Locations
🇬🇧

Local Institution, Newcastle, Tyne and Wear, United Kingdom

Oral Taxane in Combination With Pemetrexed (Alimta) in Patients With Recurrent Non-Small Cell Lung Cancer

Phase 1
Completed
Conditions
First Posted Date
2005-02-16
Last Posted Date
2010-03-02
Lead Sponsor
Bristol-Myers Squibb
Registration Number
NCT00103831
Locations
🇨🇦

Local Institution, Toronto, Ontario, Canada

BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia

First Posted Date
2005-02-15
Last Posted Date
2011-04-14
Lead Sponsor
Bristol-Myers Squibb
Registration Number
NCT00103701
Locations
🇺🇸

Local Institution, Houston, Texas, United States

Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate

Phase 2
Completed
Conditions
Interventions
First Posted Date
2005-01-14
Last Posted Date
2010-08-10
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
124
Registration Number
NCT00101816
Locations
🇬🇧

Local Institution, London, Greater London, United Kingdom

Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib

First Posted Date
2005-01-13
Last Posted Date
2012-03-02
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
387
Registration Number
NCT00101660
Locations
🇬🇧

Local Institution, London, Greater London, United Kingdom

🇨🇭

Local Instituion, Basel, Switzerland

Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia

Phase 2
Completed
Conditions
Interventions
First Posted Date
2005-01-13
Last Posted Date
2011-04-15
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
197
Registration Number
NCT00101647
Locations
🇬🇧

Local Institution, London, Greater London, United Kingdom

Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

First Posted Date
2005-01-13
Last Posted Date
2011-04-14
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
96
Registration Number
NCT00101595
Locations
🇬🇧

Local Institution, London, Greater London, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath